Cathie Wood’s ARK Invest Continues Accumulation of Intellia Therapeutics Amid Volatility
ARK Invest maintained its focused strategy with a singular trade on Thursday, acquiring $682,000 worth of Intellia Therapeutics (NTLA) shares across its Innovation and Genomic Revolution ETFs. The purchase extends a three-day buying spree, signaling conviction in the gene-editing firm despite recent clinical setbacks.
Intellia's CRISPR-based therapies face heightened scrutiny after a 23% price drop in 2025 following a patient death, yet the stock retains a 32% year-to-date gain. Analysts see 38% upside potential, framing the volatility as typical for clinical-stage biotech plays. Wood's concentrated accumulation suggests a long-term bet on genomic disruption.